Group items tagged

The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups, including "low-income," "lower-middle-income," and "upper-middle-income" countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups, including "low-income," "lower-middle-income," and "upper-middle-income" countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.  

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death.

The Children's Tumor Foundation is proud to announce the launch of the 2013 Young Investigator Award (YIA) application process. Online submission of the Pre-Applications is possible from January 14 to January 25, 2013. CTF's longest running program, YIAs provide two-year awards for young scientists early in their careers, bringing them into the NF field and helping to establish them as independent investigators.

Honoring the legacy of Paul A. Marks, MD, President Emeritus of Memorial Sloan-Kettering Cancer Center and a distinguished scientist, the Paul Marks Prize for Cancer Research recognizes outstanding young investigators who have made significant contributions to increase the understanding of cancer or improve the treatment of the disease through basic or clinical research. The Paul Marks Prize is awarded every other year to up to three investigators. The first recipients were named in 2001. The winners will present their work at a scientific symposium at Memorial Sloan-Kettering Cancer Center and share a cash award of $150,000. Nominations are now being accepted for the 2013 Paul Marks Prize for Cancer Research. Nominees must be age 45 or younger on the date of the submission deadline, April 30, 2013. Prize winners will be announced in Fall 2013.

This funding opportunity announcement (FOA) issued by ORIP, National Institutes of Health, encourages research grant applications from institutions/organizations that propose to develop, characterize or improve animal models for human disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research purposes.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions with expertise and innovative strategies for developing research and mentoring opportunities for undergraduate students from backgrounds underrepresented in biomedical research to submit applications for 6 month planning grants for the NIH Building Infrastructure Leading to Diversity (BUILD) initiative. The BUILD initiative aims to increase the diversity of the NIH-funded workforce by supporting collaborative programs that include novel approaches for enhancing undergraduate education, training, and mentorship, as well as infrastructure support and faculty development to facilitate those approaches. BUILD planning grants are intended to help institutions develop the necessary partnerships and infrastructure needed to be competitive for the BUILD initiative.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for projects that bridge biological mechanism to population level scales. By incorporating insights and data from one end of the cancer research spectrum into the framework of the other, projects should be able to cross-validate data gathered at different scales, and explore links between basic biology, population science, and potential health applications in treatment, prevention, diagnosis, and/or screening. Proposed projects should pose a challenging cancer research question that can be addressed by connecting these two ends of the research spectrum that would be difficult to address or explain through biological or epidemiological investigation alone. Only a single cohesive project integrating aspects from these two areas is allowed in each application.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage new research into integrative cancer biology by fostering collaborations between investigators currently supported through the Integrative Cancer Biology Program (ICBP) and those currently unaffiliated with the ICBP. These collaborative projects should leverage the existing expertise and resources from within the ICBP research community and combine those with new approaches, technologies or methods to address compelling cancer questions. Therefore, the proposed research projects must involve partnerships between investigators currently supported by ICBP and investigators currently unaffiliated with the program. Applications that focus on projects which neither involve integrative cancer biology research, nor expand individual ICBP investigators' research by adding additional expertise, resources, or approaches, or without affiliation to existing ICBP personnel, are not appropriate to this FOA.

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to encourage research projects which focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.

his Funding Opportunity Announcement (FOA) invites research project (R01) applications that combine imaging and biomarkers. The overall objective of this FOA is to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and diagnosis by integrating multi modality imaging strategies and multiplexed biomarker methodologies.

The purpose of this funding opportunity announcement (FOA) is to emphasize the importance of coordination and collaboration across agencies, partners, and organizations to: * improve standardized staging for use in cancer surveillance; * support and simplify the evaluation, maintenance, and updating of cancer staging applications; and * support enhancement of attributes that decrease the system's complexity.

The Fellowships team of UICC is pleased to announce the call for proposals for the 2013 Yamagiwa-Yoshida Memorial International Cancer Study Grants. Please note that the application closing date is set to 1st July 2013. Please find below some key information regarding the fellowship:  WHAT 3 months International Fellowship Award value of USD 10,000 AIMS to initiate, set-up or pursue bilateral cancer research projects with collaborating investigators abroad to receive training in advanced experimental research methods and techniques to exploit complementary skills and material WHO  Individuals with: scientific or medical qualifications and a minimum of two years postdoctoral experience actively engaged in cancer research  have recent publications in the international peer-reviewed literature

This Funding Opportunity Announcement (FOA) solicits Exploratory/Developmental Grant (R21) applications to facilitate translational research in oral cancers by supporting studies aimed at understanding the cellular, molecular, and functional properties of oral Cancer Initiating Cells (CICs) and their niches.

This Funding Opportunity Announcement (FOA) solicits Research Project Grant (R01) applications to facilitate translational research in oral cancers by supporting studies aimed at understanding the cellular, molecular and functional properties of oral Cancer Initiating Cells (CICs) and their niches.

The National Aeronautics and Space Administration (NASA) plans to release a NASA Research Announcement (NRA), for Ground-based Studies for the Space Radiation Program Element (SRPE) in the area of space radiobiology of cancer and neuronal risks utilizing beams of high energy ions simulating space radiation at the NASA Space Radiation Laboratory (NSRL) at Brookhaven National Laboratory (BNL) in Upton, New York.

This Funding Opportunity Announcement (FOA) encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer. Chemical modifications of RNA bases have been reported to regulate the fate and function of both coding and noncoding RNAs and are emerging as a critical element of post-transcriptional gene regulation. This FOA will utilize the Exploratory/Developmental (R21) mechanism which supports investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioral research.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers. The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this FOA) must be focused on cancers of the breast, prostate and other genitourinary organs, and lung. In addition, cancers with rapidly rising incidence.